Business Wire

UT-CRICUT

22.5.2021 18:07:12 CEST | Business Wire | Press release

Share
Ready, Set, Create: Cricut Unveils Innovations to Double Creativity Speeds

Makers and crafters of the world can now create faster than before with Cricut Explore® 3 and Cricut Maker® 3 . Cricut is the leader in crafting technology that lets people design, create, and personalize with its smart cutting machines. Whether you want to design beautiful decals, brighten up your walls or make personalized t-shirts for your family or friends, Cricut Explore 3 and Cricut Maker 3 cut at a speed of up to eight inches per second. It’s never been quicker or easier to get crafty.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210522005007/en/

“I’m very proud of what our team has accomplished,” said Ashish Arora, CEO at Cricut. “We wanted to take the experience to a whole new level and make sure our next generation of cutting machines make it easier on everyone to create larger projects, more projects, much faster.”

Like the earlier versions of these cutting machines, the Cricut Explore 3 and Cricut Maker 3 lets you get creative with ease using a wide variety of materials including Cricut Smart Materials® (Smart Vinyl, Smart Iron-on, Smart Paper). Creators can also now create cuts of up to 12 feet at once, putting a whole new world of creative possibilities at their fingertips.

Both machines will be available at Cricut.com on 10 June 2021 and at major retailers starting 27 June 2021.

See Your Creativity Skyrocket with Cricut Explore 3

Starting at $299 (MSRP), Cricut Explore 3 cuts over 100 materials, including cardstock, vinyl, iron-on, glitter paper and cork, letting you make an endless array of DIY projects. Delivering quality cutting performance that anyone can use, you can cut, draw, score with this machine, and embellish your projects with flawless text, detailed illustrations, or easy-to-fold creases.

Unleash Your Creativity with Cricut Maker 3

Starting at $399 (MSRP), Cricut Maker 3 is a powerful and versatile machine with the ultimate in cutting performance and versatility. This machine lets you create with more than 300 materials, from the most delicate paper and fabric to tougher materials like leather and balsa wood, all with incredible precision. Cricut Maker 3 features the Adaptive Tool System™ — the only system that intelligently controls the direction of your blade and cut pressure to match the material, and supports the widest range of tools for cutting, scoring, writing, and adding decorative effect, allowing impressive precision when making a variety of projects.

Works with Design Space

Both the Cricut Explore 3 and Cricut Maker 3 are compatible with easy-to-use Design Space software – available on desktop, iOS and Android. Whether you are new to crafting or an experienced maker, Cricut Explore 3 and Cricut Maker 3 let you make DIY magic happen anywhere, any time.

About Cricut Inc.

Cricut Inc. is a creative technology platform company dedicated to encouraging new ways for people to experience making at home. Cricut’s mission is to unleash the creative potential of its users with innovations that bring ideas to life in the form of professional-looking, personalized handmade projects. Cricut’s industry-leading products include its flagship line of smart cutting machines — the Cricut Maker® family, the Cricut Explore® family, and Cricut Joy® — accompanied by other unique tools like Cricut EasyPress®, the Infusible Ink™ system, and a diverse collection of materials. In addition to Cricut’s core offerings, the brand also fosters a thriving community of millions of dedicated users worldwide.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye